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Abstract
Unobserved confounding presents a major threat to causal inference in observational studies. Re-
cently, several authors suggest that this problem may be overcome in a shared confounding setting
where multiple treatments are independent given a common latent confounder. It has been shown
that if additional data such as negative controls are available, then the causal effects are indeed iden-
tifiable. In this paper, we show that these additional data are not necessary for causal identification,
provided that the treatments and outcome follow Gaussian and logistic structural equation models,
respectively. Our novel identification strategy is based on the symmetry and tail properties of the
observed data distribution. We further develop two-step likelihood-based estimation procedures. We
illustrate our method through simulations and a real data application studying the causal relationship
between the volume of various brain regions and cognitive scores.
Keywords: Identifiability, Latent ignorability, Shared confounding
1 Introduction
Unmeasured confounding presents a major challenge to causal inference from observational studies.
Without further assumptions, it is often impossible to identify the causal effects of interest. Classical
approaches to mitigate bias due to unmeasured confounding include instrumental variable methods (e.g.,
Angrist et al., 1996; Hernán and Robins, 2006; Wang and Tchetgen Tchetgen, 2018), causal structure
learning (e.g., Drton and Maathuis, 2017), invariant prediction (e.g., Peters et al., 2016), negative controls
(e.g., Kuroki and Pearl, 2014; Miao et al., 2018) and sensitivity analysis (e.g., Cornfield et al., 1959).
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In a recent stream of literature, several authors suggest an alternative approach to this problem by
assuming shared confounding between multiple treatments and independence of treatments given the
confounder (Wang and Blei, 2019a; Tran and Blei, 2017; Ranganath and Perotte, 2018; Wang and Blei,
2019b). This is a promising approach as it leverages information in a potentially high-dimensional
treatment to aid causal identification. Such settings are prevalent in many contemporary applications
such as genetics, recommendation systems and neuroimaging studies. Unfortunately, in general the
shared confounding structure is not sufficient for causal identification. D’Amour (2019) presents two
counterexamples: the first one involves normally-distributed treatments and outcome, and the second
one involves binary treatments and outcome. To address this non-identifiability problem, D’Amour
(2019) suggests applying classical ideas such as negative controls or sensitivity analysis to the shared
confounding setting. Along this line, Wang and Blei (2019b) show that the deconfounder algorithm of
Wang and Blei (2019a) is valid given a set of negative controls, and Veitch et al. (2019) further find a
negative control in network settings.
In this paper, we show that identification of causal effects is possible under the shared confound-
ing setting with normally-distributed treatments and a binary outcome following a logistic structural
equation model. To the best of our knowledge, this result is the first in the literature that requires no
external data but still identifies the causal effect in this setting. In contrast to the case with normally-
distributed treatments and outcome, in general the observed data distribution may contain information
beyond the first two moments, thereby providing many more non-trivial constraints for causal identifi-
cation (Bentler, 1983; Bollen, 2014). In particular, we exploit the symmetry and tail properties of the
observed data distribution to identify the causal effects. Our identification results are accompanied by
simple likelihood-based estimation procedures, and illustrations through synthetic and real data analyses.
2 Framework
LetA = (A1, A2, . . . , Ap)T be a p-vector of continuous treatments, Y be an outcome andX be a q-vector
of observed pre-treatment variables. The observed data {(Xi, Ai, Yi) : i = 1, . . . , n} are independent
samples from a super population. Under the potential outcome framework (Neyman, 1923; Rubin, 1974),
Y (a) is the potential outcome if the patient had treatment a = (a1, . . . , ap)T. We are interested in the
mean potential outcome E{Y (a)}. We make the stable unit treatment value assumption under which
Y (a) is well-defined and Y = Y (a) if A = a.
We assume the shared confounding structure under which the latent ignorability assumption holds.
Figure 1 provides a graphical illustration.
Assumption 1 (Latent ignorablity) For all a, A ⊥ Y (a) | (X,U), where U is a latent confounder.
Under Assumption 1, we have
E{Y (a)} = E{E(Y |A = a,X,U)}. (1)
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Figure 1: A graphical illustration of the shared confounding setting. The latent ignorability assumption
is encoded by the absence of arrows between Aj and Y (a) for j = 1, . . . , p. The gray node denotes that
U is unobserved.
Assuming a latent factor model for the treatments such as
U ∼ N (0, 1), A = θU + A, (2)
where A ∼ N (0, diag(σ2A,1, . . . , σ2A,p)) and A ⊥ U . Wang and Blei (2019a) suggest first constructing
an estimate of U , the so-called de-confounder, and then use (1) to identify the mean potential outcome
and causal contrasts. However, as pointed out by D’Amour (2019), E{Y (a)} is not necessarily identi-
fiable. See also Example S1 in the supplementary materials for a counterexample where Y is generated
from a Gaussian structural equation model.
3 Identification and estimation with a binary outcome
3.1 Identification and estimation without observed confounders
We now study the identification and estimation problems with a binary Y , thereby operating under a
different set of assumptions than Example S1. To fix ideas, we first consider the case without measured
confounders X and later extend these results to the case with X in § 3.2. We assume that treatments A
follow the factor model (2). We also assume the following logistic structural equation model:
pr{Y (a) = 1 | U} = pr{Y = 1 | A = a, U} = expit(α+ βTa+ γU). (3)
Since U is latent, without loss of generality, assume that γ ≥ 0. Under (2), identifiability of E{Y (a)}
amounts to identifiability of model parameters in (3).
We first note that under (2), (U,AT)T follows a joint multivariate normal distribution(
U
A
)
∼ Np+1(0,ΣJ), ΣJ =
(
1 θT
θ ΣAA
)
,
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where ΣAA = θθT + diag(σ2A,1, . . . , σ
2
A,p). Therefore, U |A = a follows a univariate normal distribution
with mean µU |a = θTΣ−1AAa and variance σ
2
U |a = 1 − θTΣ−1AAθ. Standard results from factor analysis
(Anderson and Rubin, 1956) can be used to identify ΣAA, and θ up to a sign flip.
Our identification strategy is then based on the following equation that connects the observed distri-
bution pr(Y = 1 | A = a) to the unknown structural distribution pr(Y = 1 | A = a, U = u):
pr(Y = 1 | A = a;α, β, γ, θ,ΣAA) =
∫
expit(α+ βTa+ γu)fU |A(u|a)du
=
∫
expit{α+ (βT + γθTΣ−1AA)a+ γσU |av}φ(v)dv, (4)
where φ(v) is the probability density function of a standard normal distribution. In the supplementary
materials we show that under mild conditions, there is a bijection from the functionQ(a) =
∫
expit(c1 +
cT2a + c3v)φ(v)dv to its coefficients (c1, c
T
2 , c3). This result exploits several properties of the expit
function, including its tail properties, monotonicity and symmetry around zero. It follows that one can
identify α, β and γ from (4).
We now present our main identification result, with the proof deferred to the supplementary materials.
Theorem 1 Assume that Assumption 1, models (2), (3) and the following conditions hold:
(A1) There exist at least three elements of θ = (θ1, . . . , θp)T that are non-zero, and there exists at least
one θj 6= 0, 1 ≤ j ≤ p such that the sign of θj is known a priori.
(A2) pr(Y = 1 | A = a) is not a constant function of a.
Then the parameters θ, ΣAA, α, β, γ and hence E{Y (a)} are identifiable.
Condition (A1) requires that the latent confounder U affects at least three treatments, and for at least
one of which, subject-specific knowledge allows one to determine the sign of θj . Condition (A2) requires
that the observed mean outcomes differ across treatment levels, and can be checked from the observed
data.
In parallel to our identification results, we develop a two-step estimation procedure to estimate the
model parameters. Asymptotic normality and resulting inference procedures follow directly from stan-
dard M-estimation theory.
Step 1. Find the maximum likelihood estimator (θˆ, ΣˆAA)T using off-the-shelf packages for factor anal-
ysis, such as the factanal function in R.
Step 2. Find the maximum likelihood estimator (αˆ, βˆT, γˆ)T by maximizing the conditional likelihood∏n
i=1[ri(α, β, γ)
Yi{1−ri(α, β, γ)}1−Yi ], where ri(α, β, γ) = pr(Y = 1 | A = Ai;α, β, γ, θˆ, ΣˆAA).
Monte Carlo method can be used to approximate the integral.
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3.2 Incorporating observed confounders
In the presence of observed confounders X ∈ Rq, we assume instead:
A = θU +BX + A, (5)
pr{Y (a) = 1|U,X} = expit(α+ βTa+ γU + ηTX). (6)
We also assume that (U,X,A) follows a multivariate normal distribution UX
A
 ∼ Np+q+1(0,Σ∗J), Σ∗J =
 1 ΣUX θ
T
ΣXU ΣXX ΣXA
θ ΣAX ΣAA
 .
Since both U and A are latent, without loss of generality, let X ⊥ (U, A) so that ΣUX = 0 and
ΣAX = BΣXX . If otherwise, one could project U to the orthogonal complement of the column space
of X , to obtain U∗ = (1− PX)U with PX = XT(XXT)−1X . It then holds that U∗ ⊥ X .
Let θ˜ = (0, θT)T ∈ Rp+q and Σ˜ =
(
ΣXX ΣXXB
T
BΣXX ΣAA
)
. Then U |X = x,A = a follows a
univariate normal distribution with mean µU |x,a = θ˜TΣ˜−1(xT, aT)T and variance σ2U |x,a = 1− θ˜TΣ˜−1θ˜.
Similar to (4), we have
pr(Y = 1 | A = a,X = x) =
∫
expit(α+ βTa+ γu+ ηTx)fU |A(u|x, a)du
=
∫
expit{α+ (β˜T + γθ˜TΣ˜−1)(xT, aT)T + γσU |x,av}φ(v)dv,
where β˜ = (ηT, βT)T. Identifiability of E{Y (a)} can then be obtained in a similar fashion as in § 3.1,
except that now we replace condition (A2) with the following weaker assumption:
(A2*) pr(Y = 1 | A = a,X = x) is not a constant function of (a, x)
Theorem 2 Assume that Assumption 1, models (2), (3) and assumptions (A1), (A2*) hold. Then the
parameters θ, Σ˜, α, η, β, γ and hence E{Y (a)} are identifiable.
A two-step estimation procedure proceeds as follows.
Step 1. For B, we regress A on X and obtain an estimator B̂ ∈ Rp×q. Let A∗ = A − B̂X , one can
obtain the maximum likelihood estimator of θ and Σ˜ based on a factor analysis on A∗. Denote the
estimator as θ̂ and ̂˜Σ, respectively.
Step 2. Estimate (α, βT, γ, η) by maximizing the conditional likelihood
∏n
i=1[rX,i(α, β, γ, η)
Yi{1 −
rX,i(α, β, γ, η)}1−Yi ], where rX,i(α, β, γ, η) = pr(Y = 1 | A = Ai, X = Xi;α, β, γ, η, θˆ, ̂˜Σ).
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4 Simulation
We now evaluate the finite sample performance of the proposed estimators. In our simulations, we first
generate a latent confounder U , an observed common confounder X and an additional covariate X1
from independent standard normal distributions. The treatments and outcome are then generated from
the following models:
A = θU +BX +B1X
1 + A,
pr(Y = 1|A,U,X,X1) = expit(α+ βTA+ γU + ηX + η1X1),
where θ = (1,−1, 0.5)T, α = 0, β = (1, 1, 1)T, γ = 1, and A ∼ N3(0, 0.25I3), where I3 denotes
the 3 × 3 identify matrix. We consider three settings. In setting 1, there are no observed confounders
so that B = B1 = (0, 0, 0)T , η = η1 = 0. In setting 2, there is a common confounder X with
B = (1,−1, 1)T , B1 = (0, 0, 0)T , η = 1, η1 = 0. In setting 3, there is a common confounder X and a
so-called single-cause confounder X1 with B = (1,−1, 1)T , B1 = (1, 0, 0)T , η = η1 = 1. We compare
the proposed method, assuming that we know θ1 > 0, to a naive method where we only adjust for the
observed confounders. Table 1 summarizes the results for sample size 200. Results with sample sizes
500 and 1000 are deferred to the supplementary materials.
Table 1: Simulation results for sample size 200 based on 1000 Monte Carlo samples: bias (standard
deviation) of βˆ1, βˆ2, βˆ3 and the mean potential outcomes evaluated at a(1) = (1, 1, 0)T and a(2) =
(1, 1, 1)T, are reported. In the naive method we fit the model ignoring the unobserved confounder U
Setting Method βˆ1 βˆ2 βˆ3 Eˆ{Y (a(1))} Eˆ{Y (a(2))}
1 Proposed 0.024(0.329) 0.019(0.303) 0.023(0.376) −0.006(0.069) −0.008(0.048)
Naive −0.767(0.043) −0.899(0.046) −0.803(0.055) −0.148(0.018) −0.195(0.019)
2 Proposed 0.009(0.381) 0.015(0.370) 0.037(0.439) −0.013(0.079) −0.015(0.066)
Naive −0.824(0.040) −0.926(0.042) −0.848(0.051) −0.139(0.017) −0.199(0.019)
3 Proposed 0.065(0.422) 0.034(0.424) 0.066(0.483) −0.009(0.09) −0.012(0.073)
Naive −0.851(0.040) −0.937(0.039) −0.873(0.047) −0.126(0.017) −0.193(0.019)
One can see that the estimates obtained from the naive method is subject to unmeasured confounding
bias. In contrast, the bias of our proposed estimator is small even for sample size 200, which further
reduces as the sample size grows.
5 Real data application
Understanding how human brain works and their connection to human behavior is a central goal in neu-
roscience. Studies have found that neuroimaging markers are strongly associated with behavioral deficits
6
(Whitwell et al., 2007). For example, the atrophy of three regions in the brain, the temporal, cingulate
cortex and hippocampal regions, are found to be strongly associated with symptoms of Alzheimer’s
disease (Galton et al., 2001; Choo et al., 2010; Fox et al., 1996). These associations, however, may
be confounded by common unmeasured factors such as progress of the underlying neuro-degenerative
process. We now use the proposed approach to address bias due to common unmeasured confounding.
Our analysis is based on data from the Alzheimer’s Disease Neuroimaging Initiative. This is a large-
scale observational study launched in 2003 through a $60 million, 5-year public-private partnership be-
tween the National Institutes of Health, the Food and Drug Administration and several private phar-
maceutical companies and non-profit organizations. The study recruited adults aged between 55 and 90
years old. The 800 participants include cognitively normal individuals, as well as subjects with mild cog-
nitive impairments and early Alzheimer’s disease. For more details of the study, see www.adni-info.org.
In our analysis, the treatments A1, A2 and A3 are defined as the relative volume of three brain re-
gions: the temporal, cingulate cortex and hippocampal regions; the relative volume is defined as the ratio
between the volume of a specific brain region and the total volume of the brain. The outcome is an
indicator that the Mini Mental State Examination score is smaller than 24, a measure of cognitive decline
that has been commonly used in diagnosis of Alzheimer’s disease (O’Bryant et al., 2008). The observed
confounders X include age and years of education. For illustrative purpose, we include 674 subjects
with complete covariate information in our analysis. Among these subjects, the average age is 75.3 with
a standard deviation of 6.8, and the average years of education is 15.7 with a standard deviation of 2.9.
We assume that the treatments and outcome follow models (5) and (6), respectively. It is well-known
that progress of the disease process contributes to both hippocampal atrophy and a lower Mini Mental
State Examination score (Sabuncu et al., 2011), so that θ3 ≤ 0.
Analysis results show that conditional on age, years of education and the latent disease progress, each
one percent of shrinkage in the relative volume of the temporal, cingulate cortex and hippocampal regions
causes the odds of developing a clinical relevant Alzheimer’s disease symptom, defined as the Mini
Mental State Examination score being small than 24, to increase by 0.6% with 95% confidence interval
[-1.1%, 2.3%], 1.4% with 95% confidence interval [-0.2%, 3.1%], 7.6% with 95% confidence interval
[4.0%, 11.2%], respectively. The directions of causal effect estimates are consistent with associations
reported in the literature, suggesting that the bias from latent confounding is not large enough to distort
the qualitative causal conclusions. Our results show that shrinkage of the hippocampal region has a
significant effect on the cognitive score, which aligns with the common belief that hippocampal atrophy
is among the most significant structural biomarkers of Alzheimer’s disease imaging (Henneman et al.,
2009).
We also compare the proposed and naive methods in terms of the mean potential outcomes. One
can see from Figure 2 that compared to the proposed method, the naive method suggests a much weaker
association between the shrinkage of brain regions and odds of developing Alzheimer’s disease, due to
strong confounding by the latent disease progress.
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Figure 2: Estimated mean potential Alzheimer’s disease status as a function of the relative volume of
three brain regions (in percentages). In each plot, the relative volume of the other two regions are fixed
at their sample medians
6 Discussion
We have shown identifiability of causal effects under a shared confounding setting with a logistic struc-
tural equation model for the outcome. Interestingly, these identifiability results are not necessarily true
with other structural equation models for a binary outcome. In particular, we have the following non-
identifiability result for a probit model.
Theorem 3 Suppose that the outcome Y follows a probit structural equation model that
pr{Y (a) = 1 | U} = pr(Y = 1 | A = a, U) = Φ(α+ βTa+ γU), (7)
where θ, β ∈ Rp, A ∼ N (0,diag(σ2A,1, . . . , σ2A,p)) and Φ(·) is the cumulative density function of stan-
dard normal. Then under models (2) and (7), the parameters α, β, γ and E{Y (a)} are not identifiable.
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1 Additional simulation results
In this section, we include additional simulation results. In particular, we include the simulation results
with n = 500 and n = 1000 in Tables S1.
Table S1: Simulation results based on 1000 Monte Carlo samples: bias (standard deviation) of βˆ1, βˆ2,
βˆ3 and the mean potential outcomes evaluated at a(1) = (1, 1, 0)T and a(2) = (1, 1, 1)T, are reported. In
the naive method we fit the model ignoring the unobserved confounder U
Setting Method βˆ1 βˆ2 βˆ3 Eˆ{Y (a(1))} Eˆ{Y (a(2))}
Sample size = 500
1 Proposed −0.007(0.204) −0.004(0.192) −0.002(0.236) −0.005(0.045) −0.005(0.030)
Naive −0.770(0.027) −0.902(0.029) −0.803(0.035) −0.149(0.012) −0.195(0.012)
2 Proposed 0.002(0.227) 0.001(0.224) −0.013(0.246) −0.005(0.050) −0.007(0.038)
Naive −0.823(0.025) −0.924(0.026) −0.851(0.031) −0.138(0.011) −0.198(0.012)
3 Proposed 0.021(0.253) 0.011(0.252) 0.029(0.287) −0.006(0.058) −0.006(0.045)
Naive −0.850(0.025) −0.935(0.024) −0.872(0.031) −0.126(0.011) −0.192(0.012)
Sample size = 1000
1 Proposed −0.010(0.142) −0.001(0.130) −0.016(0.160) −0.003(0.030) −0.004(0.020)
Naive −0.769(0.019) −0.901(0.020) −0.803(0.024) −0.149(0.008) −0.195(0.008)
2 Proposed −0.009(0.171) 0.006(0.158) 0.000(0.174) −0.004(0.037) −0.004(0.028)
Naive −0.823(0.018) −0.924(0.018) −0.848(0.022) −0.138(0.008) −0.198(0.008)
3 Proposed −0.003(0.172) 0.008(0.171) 0.003(0.188) −0.005(0.041) −0.005(0.033)
Naive −0.851(0.017) −0.936(0.018) −0.871(0.021) −0.126(0.007) −0.192(0.008)
2 A Counterexample
Example S1 Assume model (2) and the following model
Y (a) = βTa+ γU + Y , (S1)
1
where β = (β1, . . . , βp)T ∈ Rp, Y ∼ N (0, σ2Y ) and Y ⊥ (A,U). Under models (2) and (S1),
E{Y (a)} = E{E(Y |A = a, U)} = βTa. However, β is not identifiable.
To see this, let ΣAA ∈ Rp×p be the covariance of A, ΣAY ∈ Rp be the covariance between A and
Y , and ΣY Y ∈ R be the variance of Y . By linking the population covariance matrix of the observed
variables and model parameters, one can construct the following equations
ΣAA = θθ
T + diag(σ2A,1, . . . , σ
2
A,p), (S2)
ΣAY = ΣAAβ + γθ, (S3)
ΣY Y = (β
Tθ + γ)2 + βTdiag(σ2A,1, . . . , σ
2
A,p)β + σ
2
Y . (S4)
In this case, (S2), (S3) and (S4) are all the equations we can use to identify the parameters. In our
case, (AT, Y )T follows a multivariate normal distribution, for which the first and second moments are
sufficient statistics. The first moments contain no information for identification as they are all zero.
We will show that β is not identifiable through equations (S2), (S3) and (S4). Equation (S2) can be
used to identify θ and σA = (σ2A,1, . . . , σ
2
A,p)
T. In particular, when p ≥ 3, if there exists at least three
elements of θ = (θ1, . . . , θp)T that are non-zero, by Theorem 5.5 of Anderson and Rubin (1956), one
can identify θ up to sign flip and uniquely identify σ2A through equation (S2).
We then show that even if θ is identifiable, i.e. the sign can be determined, β is still not identifiable.
Since equation (S2) only involves θ and σA, to identify (βT, γ, σ2Y )
T ∈ Rp+2, one needs to use equations
(S3) and (S4). However, (S3) gives p equations and (S4) gives 1 equation, and the total number of
equations is only p+1. So we can not identify the p+2 dimensional parameters (βT, γ, σ2Y )
T from these
equations without assuming additional assumptions, and thus the causal effects cannot be identified.
There were some assumptions under which (βT, γ, σ2Y )
T can be identified; for example if σ2Y is
known. But this requires either we have replicates of the outcome Y or proxy of the outcome Y .
3 Proof of Theorem 1
We first present the identifiability results for θ and σ2A. When p ≥ 3, if there exist at least three elements
of θ = (θ1, . . . , θp)T that are non-zero, by Theorem 5.5 of Anderson and Rubin (1956), one can identify
θ up to sign and uniquely identify σ2A. As there exists at least one θj 6= 0, 1 ≤ j ≤ p such that the sign
of θj is known, θ is identifiable. In other words, under condition (A1), θ and σ2A are identifiable.
We then study the identifiability for α, β and γ. As A and Y are observed, the joint distribution
of (A, Y ) is identifiable. This joint distribution is uniquely determined by the distribution of A and
the conditional distribution pr(Y = 1|A = a). The distribution of A ∼ Np(0,ΣAA), where ΣAA =
θθT + diag(σ2A,1, . . . , σ
2
A,p). Then ΣAA is identified as θ and σ
2
A are identified. Define Q(a) = pr(Y =
1|A = a), which is identifiable for any a ∈ Rp.
2
One can write
Q(a) = pr(Y = 1|A = a) =
∫
pr(Y = 1|A = a, U = u)fU |A(u|a)du,
where fU |A(u|a) is the probability density function of U |A. By model (2) and the assumptions on U and
A, one can see that (U,A) is joint multivariate normal. Specifically, U
A
 ∼ Np+1(0,ΣJ),
where
ΣJ =
 1 θ
T
θ ΣAA
 .
Therefore, U |A = a is univariate normal with mean µU |a = θTΣ−1AAa and standard deviation σU |a =
(1− θTΣ−1AAθ)1/2.
Define v = (u− µU |a)/σU |a, one has
Q(a) =
∫
g(α+ βTa+ γu)fU |A(u|a)du
=
∫
g{α+ βTa+ γ(σU |av + µU |a)}φ(v)dv
=
∫
g{α+ (βT + γθTΣ−1AA)a+ γσU |av}φ(v)dv,
where φ(·) is the probability density function of standard normal.
Define c1 = α, c2 = (c21, . . . , c2p)T = β + γΣ−1AAθ and c3 = γσU |a, by condition (A1), one has
c3 > 0. We can write Q(a) =
∫
g(c1 + c
T
2a + c3v)φ(v)dv. The values of c1, c2 and c3 are determined
by the function Q(·), which we show in the following proof.
We first identify c21. DefineQ1(a1) = pr(Y = 1|A1 = a1, A2 = 0, . . . , Ap = 0) = Q(a)|a2=0,...,ap=0 =∫
g(c1 + c21a
1 + c3v)φ(v)dv. When c21 > 0, one can see that
lim
a1→+∞
Q1(a
1) = lim
a1→+∞
∫
g(c1 + c21a
1 + c3v)φ(v)dv =
∫
lim
a1→+∞
g(c1 + c21a
1 + c3v)φ(v)dv = 1.
Here the integration and limit are exchangeable as g and φ are bounded. As the sigmoid function satisfies
3
g′ = g(1− g), one has
lim
a1→+∞
Q′1(a
1) = lim
a1→+∞
c21
∫
g(c1 + c21a
1 + c3v){1− g(c1 + c21a1 + c3v)}φ(v)dv
= c21
∫
lim
a1→+∞
g(c1 + c21a
1 + c3v){1− g(c1 + c21a1 + c3v)}φ(v)dv = 0
Here the integration and limit are exchangable as g, g′ and φ are bounded. Therefore, one has
lima1→+∞Q′1(a1)/Q1(a1) = 0.
Next, we calculate
Q′1(a
1)/Q1(a
1) =
c21
∫
g(c1 + c21a
1 + c3v){1− g(c1 + c21a1 + c3v)}φ(v)dv∫
g(c1 + c21a1 + c3v)φ(v)dv
= c21 − c21
∫
g2(c1 + c21a
1 + c3v)φ(v)dv∫
g(c1 + c21a1 + c3v)φ(v)dv
.
As g(t) ≤ exp(t) for any t, one has∫
g2(c1 + c21a
1 + c3v)φ(v)dv ≤
∫
exp(2c1 + 2c21 + 2c3v)φ(v)dv = exp(2c1 + 2c21 + 2c
2
3)
Notice that g(t) ≥ 0.5 exp(t) for any t < 0. As c3 = γσU |a ≥ 0, for t < −c1/c21, one has∫
g(c1 + c21a
1 + c3v)φ(v)dv ≥
∫ 0
−∞
g(c1 + c21a
1 + c3v)φ(v)dv
≥ 0.5
∫ 0
−∞
exp(c1 + c21a
1 + c3v)φ(v)dv
= 0.5 exp(c1 + c21a
1)
∫ 0
−∞
exp(c3v)φ(v)dv
= 0.5 exp(c1 + c21a
1 + 0.5c23)Φ(−c3),
where Φ(·) is the cumulative density function of standard normal.
We can see that
0 ≤ lim
a1→−∞
∫
g2(c1 + c21a
1 + c3v)φ(v)dv∫
g(c1 + c21a1 + c3v)φ(v)dv
≤ lim
a1→−∞
exp(2c1 + 2c21a
1 + 2c23)
0.5 exp(c1 + c21a1 + 0.5c23)Φ(−c3)
= 0.
Consequently, lima1→−∞Q′1(a1)/Q1(a1) = c21. When c21 > 0, one has lima1→+∞Q′1(a1)/Q1(a1) =
0 and lima1→−∞Q′1(a1)/Q1(a1) = c21.
Similarly, when c21 < 0, one can show that lima1→+∞Q′1(a1)/Q1(a1) = c21 and
lima1→−∞Q′1(a1)/Q1(a1) = 0. When c21 = 0, Q′1(a1) = 0 for any a1 ∈ R, and thus
lima1→+∞Q′1(a1)/Q1(a1) = 0 and lima1→−∞Q′1(a1)/Q1(a1) = 0. Combining all the scenarios, one
can identify c21 by c21 = lima1→+∞Q′1(a1)/Q1(a1) + lima1→−∞Q′1(a1)/Q1(a1).
Analogously, define Qj(aj) = pr(Y = 1|A1 = 0, A2 = 0, . . . , Aj = aj , . . . , Ap = 0) =
4
Q(a)|a1=0,...,aj−1=0,aj+1=0,ap=0 =
∫
g(c1+c2ja
j+c3v)φ(v)dv, one has c2j = limaj→+∞Q′j(a
j)/Qj(a
j)+
limaj→−∞Q′j(a
j)/Qj(a
j) for 1 ≤ j ≤ p, and thus c2 can be identifiable.
As φ(·) is a symmetric function, one has ∫ g(c3v)φ(v)dv = g(0) = 0.5. By condition (A2), there
exists j such that c2j 6= 0, thus one hasQj(−c1/c2j) = 0.5. AsQ′j(aj) = c2j
∫
g(c1 +c2ja
j +c3v){1−
g(c1 +c2ja
1 +c3v)}φ(v)dv, Q′j(aj) has the same sign as c2j , and thereforeQj(aj) is strictly monotone,
i.e. it is strictly increasing if c2j > 0 and strictly decreasing if c2j < 0. Thus, Q−1j exists, and one has
c1 = −Q−1j (0.5)c2j .
Define a function K : R+0 → R by K(s) =
∫
g(1 + sv)φ(v)dv, where R+0 denotes the set of all
positive real numbers. We first prove that the function is strictly monotone on R+0 , and thus invertible on
R+0 . To show this, we calculate the derivative of K(s) as K ′(s) =
∫
g′(1 + sv)vφ(v)dv.
For positive v and s, one has |1 + sv| > |1− sv|, and therefore g′(1 + sv) < g′(1− sv). As φ(·) is
symmetric, we have ∫ ∞
0
g′(1 + sv)vφ(v)dv <
∫ ∞
0
g′(1− sv)vφ(v)dv
=
∫ −∞
0
g′(1 + sv)vφ(v)dv
= −
∫ 0
−∞
g′(1 + sv)vφ(v)dv.
Consequently, K ′(s) =
∫
g′(1 + sv)vφ(v)dv =
∫∞
0 g
′(1 + sv)vφ(v)dv+
∫ 0
−∞ g
′(1 + sv)vφ(v)dv < 0
for all s > 0. This implies K(·) is strictly monotone on R+0 , and thus invertible on R+0 . If there exists a
c2j 6= 0, one has K(c3) = Qj{(1− c1)/c2j}, and therefore c3 = K−1[Qj{(1− c1)/c2j}].
As c1 = α, c2 = (c21, . . . , c2p)T = β + γΣ−1AAθ and c3 = γσU |a, the parameters can be solved
by α = c1, γ = c3σ−1U |a and β = c2 − γΣ−1AAθ by noticing that both σU |a and ΣAA have already been
identified through the factor model (2).
In sum, α, β and γ can be identified through the following equations,
α = c1, (S5)
β = c2 − γΣ−1AAθ, (S6)
γ = c3(1− θTΣ−1AAθ)1/2, (S7)
where θ and Σ−1AA are identified through the factor model (2). The c1, c2 = (c21, . . . , c2p)
T ∈ Rp and c3
are identified through
c2j = lim
aj→+∞
Q′j(a
j)/Qj(a
j) + lim
aj→−∞
Q′j(a
j)/Qj(a
j) for 1 ≤ j ≤ p,
c1 = −Q−1j (0.5)c2j ,
c3 = K
−1[Qj{(1− c1)/c2j}],
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for some c2j 6= 0. Thus E{Y (a)} = E{E(Y |A = a, U)} =
∫
g(α+ βTa+ γu)φ(u)du is identifiable.
Remark 1 If c2j = 0 for all 1 ≤ j ≤ p, Q(a) = pr(Y = 1) for any a, and we have pr(Y = 1) =∫
g(c1 + c3v)φ(v)dv. In this case we can not identify c1 and c3 as we have two parameters, but only one
equation. Therefore, the parameters are not identifiable.
4 Proof of Theorem 3
The identifiability results for θ and σ2A are the same as that in proof of Theorem 1. In particular, under
condition (A1), one can identify θ and σ2A.
We will show under models (2) and (7), E{Y (a)} is not identifiable. One can write
Q(a) =
∫
Φ(α+ βTa+ γu)fU |A(u|a)du
=
∫
Φ{α+ βTa+ γ(σU |av + µU |a)}φ(v)dv
=
∫
Φ{α+ (βT + γθTΣ−1AA)a+ γσU |av}φ(v)dv,
where φ(·) is the probability density function of standard normal.
Define c1 = α, c2 = (c21, . . . , c2p)T = β + γΣ−1AAθ and c3 = γσU |a, one can write
Q(a) =
∫
Φ(c1 + c
T
2a+ c3v)φ(v)dv
=
∫ ∞
−∞
∫ c1+cT2 a+c3v
−∞
φ(u)duφ(v)dv
= pr(Z1 < c1 + c
T
2a+ c3Z2)
= pr(Z1 − c3Z2 < c1 + cT2a)
= Φ{(c1 + cT2a)(1 + c23)−1/2},
where Z1 and Z2 are two independent standard normal random variables.
One can see Y |A follows a probit model with intercept c1(1 + c23)−1/2 and regression slopes (1 +
c23)
−1/2c2, and therefore c1(1+c23)−1/2 and (1+c23)−1/2c2 are identifiable byQ(a), say c1(1+c23)−1/2 =
k1 ∈ R and (1 + c23)−1/2c2 = k2 ∈ Rp. Meanwhile the values k1 and k2 uniquely determine Q(a).
Therefore, for any (c1, cT2 , c3)
T, as long as they satisfy c1(1 + c23)
−1/2 = k1 and (1 + c23)−1/2c2 = k2,
they are the solutions. One can easily see there are infinite solutions, and therefore (c1, cT2 , c3)
T is not
identifiable. As α = c1, γ = c3(1 − θTΣ−1AAθ)1/2 and β = c2 − γΣ−1AAθ, one can see α, β and γ have
infinite solutions and are not identifiable.
We will then show that there exist two sets of solutions (α, βT, γ)T such thatE{Y (a)} = E{E(Y |A =
a, U)} = ∫ Φ(α+ βTa+ γu)φ(u)du = Φ{(α+ βTa)(1 + γ2)−1/2} have different values.
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As c1(1 + c23)
−1/2 = k1 and (1 + c23)−1/2c2 = k2, one solution for (c1, cT2 , c3)T is (k1, kT2 , 0)T. We
then obtain α = k1, β = k2 and γ = 0, and the mean potential outcome E{Y (a)} = Φ(k1 + kT2 a).
Another solution for (c1, cT2 , c3)
T is (2k1, 2kT2 ,
√
3)T. We can obtain α = 2k1, β = 2k2 −
√
3(1 −
θTΣ−1AAθ)
1/2Σ−1AAθ and γ =
√
3(1− θTΣ−1AAθ)1/2. In this case, the mean potential outcome E{Y (a)} =
Φ{[2k1+{2k2−
√
3(1−θTΣ−1AAθ)1/2Σ−1AAθ}Ta](4−3θTΣ−1AAθ)−1/2}. One can see two sets of solutions
for (c1, cT2 , c3)
T give two different mean potential outcomes, and thus E{Y (a)} is not identifiable.
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